HONG KONG/SINGAPORE (Reuters) - GlaxoSmithKline has sold its stake in Unilever's Indian business for $3.4 billion(2.75 billion pounds), marking India's largest block trade, which will help the British ...

GlaxoSmithKline has offloaded a chunk of its consumer health business in a deal that earned the company more proceeds than expected. On Thursday, GSK said it sold its entire 5.7% stake in Unilever’s ...

British pharmaceutical giant GlaxoSmithKline (GSK) has entered India’s oncology space with the launch of two advanced therapies, Jemperli (dostarlimab) and Zejula (niraparib), in a move that goes ...

GSK has announced the availability of its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, marking its commitment to addressing the unmet need for specialised ...

BENGALURU, Feb 7 (Reuters) - GlaxoSmithKline Pharmaceuticals Ltd GLAX.NS, the Indian unit of UK's GSK plc GSK.L, reported a 9.5% rise in third-quarter profit on Tuesday, in line with analysts' ...

British drugmaker GlaxoSmithKline plc is planning a sale of its $3.7 billion stake in Unilever Ltd's listed India unit, Bloomberg News reported https://www.bloomberg ...

GlaxoSmithKline Pharmaceuticals Ltd. (GSK India) reported a net profit growth of 3.3% to of ₹255 crore for the quarter ended September 30, 2025, despite seasonal and supply chain challenges. Revenue ...

GlaxoSmithKline has said it would keep an open mind about how to exit the Pfizer-partnered consumer health joint venture. But a sale at $68 billion apparently isn't an option. GSK has rejected three ...

GSK trades at lower price multiples compared to competitors due to weaker pipeline. GSK's revenue growth in 2023 was modest, but it has strong performers in its product mix. GSK needs to demonstrate ...

AbbVie and GSK are both solid investment choices in the biopharmaceutical industry. AbbVie's financials and forward outlook show strong performance alongside solid partnerships, which hint at growth ...